Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the…
FAIL · Does not pass the screen
8.37 USD
At the last full screen 2026-08-27
Screened 2026-08-27 · the tape above runs as of 22:12 UTC · 11 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its markup label.
Maravai LifeSciences Holdings, Inc. holds its Markup at $8.37. Consolidating, no directional conviction, held for 13 days.
As held on the ledger · 2026-08-27
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 13 days
Price at the screen
$8.37
Valuation
N/A trailing · -83.37 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.58
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
47.33%
Below 33%
Interest-bearing debt is 47.3% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
31.46%
Below 49%
Money owed to the company is 31.5% of assets, under the 49% limit.
Pass
Revenue purity
6.16%
Below 5%
6.2% of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-08-27 screen. The gold marker is the market price at the same screen. The price runs 16.4% above the base estimate.
Third-party analyst targets: 5 covering, consensus Buy. The average target sits −16% from the screen price.
Reading the gap · Both our model and the Street see limited upside at this price.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-08-27 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Biotech Tools Firm Loses Money At Scale
Every vaccine or cell therapy that reaches a lab still needs the right reagents and enzymes to get made. Maravai supplies some of those inputs across North America and beyond. Revenue is rising fast at 40 percent, yet the company posts a 51 percent negative profit margin and negative 41 percent return on equity.
We pass because the shares trade at 7.24 dollars against our 6 dollar fair value, a negative 17 percent margin of safety, and a forward price to earnings ratio of negative 78.9 times. Five analysts call it a buy with a 6 dollar median target, but the numbers show a business that is not yet converting growth into profit.
Currency moves, customer concentration and the usual biotech funding cycles add real downside. The ethical screen clears, yet the financial profile does not. Analysis, not advice.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
MRVI trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-09-05Markup$8.37+15.6%Entry 5
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 15.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 40% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 134%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (5 analysts) rates it none, with a mean price target of $6.
2026-08-06Markup$7.24+45.4%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 45.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 40% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 134%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (5 analysts) rates it none, with a mean price target of $6.
2026-07-18Markup$4.98+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 40% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 134%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (5 analysts) rates it none, with a mean price target of $6.
2026-07-03Markup$4.98+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Markup$4.98Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
